Detection method for determining BMP in human plasma
Through liquid-liquid extraction method and liquid chromatography-tandem mass spectrometry, combined with pheromon Luna column and electrospray ion source, rapid and sensitive quantitative analysis of BMP in rat and dog serum was achieved, and quantitative in the prior art was solved The problem of insufficient analysis methods is suitable for the detection requirements of large-scale research samples.
Patent Information
- Application Number
- CN202411072239.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, there are few quantitative analysis methods for di-22:6-BMP and lack sensitive, fast and convenient detection methods, which are difficult to meet the analysis needs of large-scale research samples.
The serum samples were pretreated by liquid-liquid extraction, combined with liquid chromatography-tandem mass spectrometry, and using pheromon Luna column and electrospray ion source, quantitative analysis of BMP was achieved through gradient elution and negative ion detection, with a detection time of 3 minutes. , the sample usage is small, suitable for preclinical research and large-scale sample analysis.
It realizes sensitive and high quantitative analysis of BMP in rat and dog serum, with the lower limit concentration of 0.2ng/mL, fast detection speed, suitable for large-scale research sample analysis, simple operation, and suitable for preclinical research.
Smart Images

Figure CN119000970A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a method for detecting BMP in rat and dog serum. Background Art
[0002] Drug-induced phospholipidosis (DIPL) is a phospholipid storage disorder characterized by abnormal accumulation of multilamellar bodies (myeloid bodies) in cells and tissues. Currently, more than 350 candidate drugs and marketed drugs have been reported to cause DIPL. Most compounds that cause DIPL are cationic amphiphilic (lipophilic).
[0003] In nonclinical studies, a specific BMP, di22:6-BMP, is a reliable biomarker for tissue DIPL that can be monitored in plasma / serum and urine. The use of di-22:6-BMP as a non-invasive biomarker for DIPL provides a method to monitor the time course of DIPL and drug toxicity, including the onset and recovery time of relevant organ systems.
[0004] Due to the interconnectedness between BMPs, lysosomal function, and phospholipid accumulation, changes in di-22:6-BMP may serve as a sensitive marker for early DIPL. Studies have shown that di-22:6BMP is more predictive of DIPL and less correlated with tissue damage than other phospholipids, making it a more specific marker for DIPL. Furthermore, the concentration of di-22:6-BMP in humans and experimental animals can be accurately quantified using bioanalytical methods such as LC-MS / MS.
[0005] In 2012, Karol L. Thompson et al. established a liquid chromatography-tandem mass spectrometry method to determine di-22:6-BMP in rat urine, but the main purpose of the method was to discover the specificity of di-22:6-BMP and other phospholipids that can increase urinary renal toxicity for DIPL.
[0006] Nanjun Liu, Elizabeth A et al. used liquid chromatography-tandem mass spectrometry to determine the concentration of di-22:6-BMP in human serum, plasma and urine in 2014, but the main purpose of this study was to demonstrate the relevance of di-22:6-BMP as a DIPL biomarker for human drug development and safety assessment.
[0007] In summary, there are currently few studies on the determination of di-22:6-BMP by LC-MS / MS, and the relevant studies do not describe the analytical methods in detail. Therefore, a sensitive, rapid, and convenient analytical method is needed to quantitatively analyze and detect di-22:6-BMP. Summary of the invention
[0008] In order to solve the above technical problems, the purpose of the present invention is to provide a method for detecting BMP in rat and dog serum.
[0009] To achieve the above object, the present invention adopts the following technical solution:
[0010] The method for determining BMP in rat and dog serum comprises the following steps:
[0011] Pretreatment: collect serum, add internal standard solution, add isopropanol and distilled water, take supernatant after vortexing and centrifugation, blow dry with nitrogen, add resolvent and vortex to mix to obtain the sample to be tested;
[0012] Chromatography, the sample to be tested was separated by liquid chromatography, using a Pheomenon Luna column, gradient elution, elution time of 3 min, flow rate of 0.5 mL / min, column temperature of 50 ° C, automatic sampler temperature of 4 ° C, injection volume of 5.0 μL, mobile phase A was an aqueous solution containing 0.02% ammonia, and mobile phase B was isopropanol containing 0.02% ammonia.
[0013] Mass spectrometry, using electrospray ion source, negative ion detection, capillary voltage 3.00 kV, desolvation temperature 600 ° C, desolvation gas flow rate 1000 L / Hr, BMP quantitative analysis ion pair m / z 865.2 → 327.1, Cone voltage (CV) 30 V, Collision energy (CE) 30 eV. 14:0 BMP (S, R) quantitative analysis ion pair m / z 665.2 → 227.0, Cone voltage (CV) 30 V, Collision energy (CE) 35 eV.
[0014] Preferably, the detection method for determining BMP in rat and dog serum is characterized in that: in the pretreatment step, the unknown sample is pretreated, and 100 μL of serum sample is taken. Then, 50.0 μL of internal standard solution (14:0 BMP (S, R) 1.00 ng / mL), 100 μL of isopropanol and 100 μL of distilled water are added respectively, and then 500 μL of ethyl acetate is added, vortexed and mixed, centrifuged (4°C, 12000 rpm, 5 min), 500 μL of supernatant is taken, 40°C, nitrogen is blown dry, 200 μL of redissolving agent (isopropanol: distilled water = 1:1) is added for redissolution, 5.00 μL of sample is taken for injection after vortex mixing. The standard curve and quality control samples are prepared using a solution containing 5% bovine serum albumin.
[0015] Preferably, the method for detecting BMP in rat and dog serum is characterized in that the internal standard solution is 14:0 BMP (S, R).
[0016] Preferably, the method for detecting BMP in rat and dog serum is characterized in that the mass spectrometer uses negative ion detection and detects the parent ion of BMP, which is m / z 865.2.
[0017] Preferably, the method for determining BMP in rat and dog serum is characterized in that: in the chromatography step, a Pheromon Luna column is used, mobile phase A is an aqueous solution containing ammonia, and mobile phase B is isopropanol containing ammonia.
[0018] By means of the above scheme, the present invention has at least the following advantages:
[0019] 1. The present invention has high sensitivity, and the lower limit of BMP quantification concentration is 0.2 ng / mL.
[0020] 2. The sample amount of the present invention is as small as 100 μL, which is suitable for preclinical research.
[0021] 3. The present invention has a fast detection speed, and the detection time is 3.0 min, which is suitable for large-scale research sample analysis.
[0022] 4. The present invention adopts liquid-liquid extraction method for pretreatment, which is easy to operate and suitable for large-scale research sample analysis.
[0023] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the following is a detailed description of the preferred embodiments of the present invention in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0025] Figure 1 Figure 2 is the MRM chromatogram of BMP and internal standard in double blank matrix samples.
[0026] Figure 2 Figure 2 is the MRM chromatogram of BMP and internal standard in a single blank matrix sample.
[0027] Figure 3 It is the MRM chromatogram of BMP and internal standard in the sample with lower limit of quantification.
[0028] Figure 4 It is the MRM chromatogram of BMP and internal standard in the quantitative upper limit sample.
[0029] Figure 5Figure 2 is the MRM chromatogram of BMP and internal standard in unknown serum samples. DETAILED DESCRIPTION
[0030] The present invention is further described in detail in conjunction with the following specific examples and drawings, and the protection content of the present invention is not limited to the following examples. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention, and the attached claims are the scope of protection. The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention does not specifically limit the content.
[0031] The development of a method for detecting drug concentration in plasma by liquid chromatography-tandem mass spectrometry can generally be divided into three parts, namely, extraction method (i.e., pretreatment method), liquid chromatography method, and mass spectrometry method. The present invention aims at the shortcomings of the prior art and establishes a detection method from the above three aspects.
[0032] Example
[0033] Pre-treatment
[0034] The amount of serum used in the present invention is only 100 μL. The extraction method of the present invention adopts liquid-liquid extraction method, which has a high recovery rate for BMP and is simple to operate, short extraction time, and is suitable for high-throughput sample pretreatment in preclinical research.
[0035] The specific pre-processing steps are as follows:
[0036] Standard curve and quality control sample preparation:
[0037] 1. Prepare the standard curve and quality control samples using a 5% bovine serum albumin solution and add 100 μL to a 1.5 mL EP tube;
[0038] 2. Add 50.0 μL of internal standard solution (14:0 BMP (S, R) concentration is 1.00 ng / mL);
[0039] 3. Add 100 μL isopropanol, 100 μL distilled water and 500 μL ethyl acetate; vortex for 5 min and centrifuge for 5 min (14000 rpm);
[0040] 4. Take 500 μL of supernatant and blow dry with nitrogen;
[0041] 5. Add 200 μL of resolvent, vortex mix, and place in an automatic sampler for LC-MS / MS analysis;
[0042] 6. The injection volume is 5.0 μL.
[0043] Unknown sample preparation:
[0044] 1. Add 100 μL of serum sample to a 1.5 mL EP tube;
[0045] 2. Add 50.0 μL of internal standard solution (14:0 BMP (S, R) concentration is 1.00 ng / mL);
[0046] 3. Add 100 μL isopropanol, 100 μL distilled water and 500 μL ethyl acetate; vortex for 5 min and centrifuge for 5 min (14000 rpm);
[0047] 4. Take 500 μL of supernatant and blow dry with nitrogen;
[0048] 5. Add 200 μL of resolvent, vortex mix, and place in an automatic sampler for LC-MS / MS analysis;
[0049] 6. The injection volume is 5.0 μL.
[0050] Mass spectrometry
[0051] Electrospray ion source, negative ion detection, capillary voltage 3.00 kV, desolvation temperature 600 ° C, desolvation gas flow rate 1000 L / Hr, residence time 0.044 s, BMP quantitative analysis ion pair m / z 865.2 → 327.1, Cone voltage (CV) 30 V, Collision energy (CE) 30 eV. 14:0 BMP (S, R) quantitative analysis ion pair m / z 665.2 → 227.0, Cone voltage (CV) 30 V, Collision energy (CE) 35 eV.
[0052] Chromatography
[0053] The sample to be tested was separated by liquid chromatography using a Pheome Luna column, gradient elution, elution time of 3 min, flow rate of 0.5 mL / min, column temperature of 50°C, automatic sampler temperature of 4°C, injection volume of 5.0 μL, mobile phase A was an aqueous solution containing 0.02% ammonia, mobile phase B was isopropanol containing 0.02% ammonia, and the Pheome Luna column was 50 mm in length and 4.6 mm in diameter.
[0054] BMP is well retained under the conditions of gradient elution, and can be eluted in a shorter time by gradient elution. The method adopts the ionization mode of negative ions during mass spectrometry detection, and the addition of ammonia water in the mobile phase can promote the generation of negative ions and improve the mass spectrometry response. The mobile phase is alkaline due to the addition of ammonia water. The present invention adopts the Pheromone Luna column, which has a wide pH application range and can be used for alkaline, neutral or acidic compounds, and can tolerate alkaline mobile phases. The chromatographic running time of the present invention is only 3.0min, and the detection is fast and suitable for the research of large-scale sample detection.
[0055] Embodiment 1:
[0056] Abbreviation
[0057]
[0058] 1 Materials
[0059] 1.1 Instrument
[0060] Chromatography: Liquid chromatography system includes Sample Manager-FL autosampler, Binary SolventManager pump system, Column Heater-A column oven, Sample Organizer sample manager, Waters Company. Mass spectrometer: Xevo TQ-XS triple quadrupole tandem mass spectrometer equipped with electrospray ionization source (ESI source), Waters Company.
[0061] Data processing software used: MassLynx V4.2, Waters Corporation.
[0062] Centrifuge: 5810R, Eppendorf.
[0063] Analytical balance: AB265-S, Mettler-Toledo Instruments (Shanghai) Co., Ltd.
[0064] 1.2 Reference substances and reagents
[0065] BMP and 14:0BMP (S, R) were purchased from Company, chromatographically pure isopropanol was purchased from Merrill, bovine serum albumin was purchased from Maclean Co., Ltd., analytical alcohol ammonia water was purchased from Shanghai Lingfeng Co., Ltd., and distilled water was Watsonswater.
[0066] 2 Methods
[0067] 2.1 Preparation of solutions and samples
[0068] Standard series samples: Prepare a stock solution with a BMP concentration of about 1.00 mg / mL. Accurately pipette an appropriate amount of each stock solution and dilute it step by step with isopropanol to obtain a mixed standard series sample with a BMP concentration range of 0.200-20.0 ng / mL.
[0069] Quality control samples: Prepare a stock solution with a BMP concentration of approximately 1.00 mg / mL. Accurately pipette an appropriate amount of each stock solution and dilute it stepwise with isopropanol to obtain quality control samples. The lower limit of quantification (LLOQ) concentration is 0.200 ng / mL, the low quality control (LQC) concentration is 0.600 ng / mL, the medium quality control (MQC) concentration is 6.00 ng / mL, and the high quality control (HQC) concentration is 15.0 ng / mL.
[0070] Internal standard solution: Prepare a stock solution of 14:0 BMP (S, R) with a concentration of about 1.00 mg / mL. Accurately pipette an appropriate amount of each stock solution and dilute it stepwise with 50% isopropanol to obtain a 1.00 ng / mL internal standard working solution.
[0071] 2.2 Serum sample processing
[0072] Add 100 μL of serum sample to a 1.5 mL EP tube, add 50.0 μL of internal standard solution (14:0 BMP (S, R) concentration is 1.00 ng / mL), add 100 μL of isopropanol, 100 μL of distilled water and 500 μL of ethyl acetate, vortex for 5 min, centrifuge for 5 min (14000 rpm), take 500 μL of supernatant, and blow dry with nitrogen. Add 200 μL of resolvent, vortex to mix, place in an automatic sampler for LC-MS / MS analysis, and the injection volume is 5.0 μL. The standard curve and quality control samples are prepared using a 5% bovine serum albumin solution, and 100 μL is added to a 1.5 mL EP tube.
[0073] 2.3 Chromatographic and mass spectrometry conditions
[0074] Chromatographic conditions
[0075] Chromatographic column: Phenomenon Luna 5um 100A LC 50*4.6mm.
[0076] Mobile phase A: aqueous solution containing 0.02% ammonia.
[0077] Mobile phase B: isopropanol containing 0.02% ammonia.
[0078] Gradient elution:
[0079] Time(min) Flow(mL / min) %A %B Curve 1 Initial 0.500 75.0 25.0 Initial 2 1.00 0.500 40.0 60.0 6 3 1.80 0.500 40.0 60.0 6 4 1.90 0.500 5.0 95.0 6 5 2.40 0.500 5.0 95.0 6 6 2.50 0.500 75.0 25.0 6 7 3.00 0.500 75.0 25.0 6
[0080] Column temperature: 50℃.
[0081] Injection volume: 5.0 μL.
[0082] Autosampler temperature: 4°C.
[0083] Mass spectrometry conditions
[0084] Electrospray ion source, negative ion detection, capillary voltage 3.00 kV, desolvation temperature 600 ° C, desolvation gas flow rate 1000 L / Hr, BMP quantitative analysis ion pair m / z 865.2 → 327.1, Cone voltage (CV) 30 V, Collision energy (CE) 30 eV. 14:0 BMP (S, R) quantitative analysis ion pair m / z 665.2 → 227.0, Cone voltage (CV) 30 V, Collision energy (CE) 35 eV.
[0085] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the technical principles of the present invention, and these improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A method for determining BMP in rat and dog serum, characterized in that: The following steps are involved: Pretreatment of unknown samples: collect serum, add internal standard solution, add isopropanol, distilled water and ethyl acetate, vortex and centrifuge, take the supernatant, blow dry with nitrogen, add resolvent to dissolve, vortex and mix to obtain the sample to be tested; standard curve and quality control samples are prepared using a solution containing 5% bovine serum albumin. Chromatography: The samples to be tested were separated by liquid chromatography using a Pheomenon Luna column, gradient elution, elution time of 3 min, flow rate of 0.5 mL / min, column temperature of 50 ° C, automatic sampler temperature of 4 ° C, injection volume of 5.0 μL, mobile phase A was an aqueous solution containing 0.02% ammonia, and mobile phase B was isopropanol containing 0.02% ammonia. Mass spectrometry, using electrospray ion source, negative ion detection, capillary voltage 3.00 kV, desolvation temperature 600 ° C, desolvation gas flow rate 1000 L / Hr, BMP quantitative analysis ion pair m / z 865.2 → 327.1, Cone voltage (CV) 30 V, Collision energy (CE) 30 eV. 14:0 BMP (S, R) quantitative analysis ion pair m / z 665.2 → 227.0, Cone voltage (CV) 30 V, Collision energy (CE) 35 eV.
2. The method for detecting BMP in rat and dog serum according to claim 1, characterized in that: The pretreatment step, in which the unknown sample is pretreated, takes 100 μL of serum sample. Then, 50.0 μL of internal standard solution (14:0 BMP (S, R) 1.00 ng / mL), 100 μL of isopropanol and 100 μL of distilled water are added respectively, and then 500 μL of ethyl acetate is added, vortexed and mixed, centrifuged (4°C, 12000 rpm, 5 min), 500 μL of supernatant is taken, 40°C, nitrogen blown dry, 200 μL of resolvent (isopropanol: distilled water = 1:1) is added for re-dissolution, vortexed and mixed, and 5.00 μL of sample is taken for injection. The standard curve and quality control samples are prepared using a solution containing 5% bovine serum albumin.
3. The method for detecting BMP in rat and dog serum according to claim 2, characterized in that: The internal standard solution is 14:0 BMP (S, R).
4. The method for detecting BMP in rat and dog serum according to claim 1, characterized in that: The mass spectrometer uses negative ion detection and detects the parent ion of BMP in rat and dog serum, which is m / z 865.
2.
5. The method for detecting BMP in rat and dog serum according to claim 1, characterized in that: In the chromatography step, a Pheomenon Luna column is used, mobile phase A is an aqueous solution containing ammonia, and mobile phase B is isopropanol containing ammonia.
